Levosalbutamol

Levosalbutamol
Clinical data
Trade names	Xopenex, other
Other names	evalbuterol
AHFS/Drugs.com	International Drug Names
License data	US DailyMed: Levalbuterol;
Pregnancy; category	AU: A; ;
Routes of; administration	By mouth (tablets), inhalational (MDI)
Legal status
Legal status	US: WARNINGRx-only;
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	3.3–4 hours
Excretion	Urinary
Identifiers
	IUPAC name 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]- 2-(hydroxymethyl)phenol;
CAS Number	34391-04-3 ;
PubChem CID	123600;
DrugBank	DB01001 ;
ChemSpider	110192 ;
UNII	EDN2NBH5SS;
KEGG	D08124 ;
ChEBI	CHEBI:8746 ;
ChEMBL	ChEMBL1002 ;
CompTox Dashboard (EPA)	DTXSID80187964 ;
ECHA InfoCard	100.113.688
Chemical and physical data
Formula	C13H21NO3
Molar mass	239.315 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OCc1cc(ccc1O)[C@@H](O)CNC(C)(C)C;
	InChI InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/m0/s1 ; Key:NDAUXUAQIAJITI-LBPRGKRZSA-N ;
	(what is this?) (verify)

Levosalbutamol, also known as levalbuterol, is a short-acting β₂ adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Evidence is inconclusive regarding the efficacy of levosalbutamol versus salbutamol or salbutamol-levosalbutamol combinations, though levosalbutamol is believed to have a better safety profile due to its more selective binding to β₂ receptors (primarily in the lungs) versus β₁ (primarily in heart muscle).^[2]^[3]

The drug is the (R)-(−)-enantiomer of its prototype drug salbutamol. It is available in some countries in generic formulations from pharmaceutical companies including Cipla, Teva, and Dey, among others.

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ Jat KR, Khairwa A (April 2013). "Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis". Pulmonary Pharmacology & Therapeutics. 26 (2): 239–248. doi:10.1016/j.pupt.2012.11.003. PMID 23207739.
^ Punj A, Prakash A, Bhasin A (November 2009). "Levosalbutamol vs racemic salbutamol in the treatment of acute exacerbation of asthma". Indian Journal of Pediatrics. 76 (11): 1131–1135. doi:10.1007/s12098-009-0245-4. PMID 20012785. S2CID 11566782.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

[Jat2013-2] Jat KR, Khairwa A (April 2013). "Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis". Pulmonary Pharmacology & Therapeutics. 26 (2): 239–248. doi:10.1016/j.pupt.2012.11.003. PMID 23207739.

[3] Punj A, Prakash A, Bhasin A (November 2009). "Levosalbutamol vs racemic salbutamol in the treatment of acute exacerbation of asthma". Indian Journal of Pediatrics. 76 (11): 1131–1135. doi:10.1007/s12098-009-0245-4. PMID 20012785. S2CID 11566782.

[1]

[2]

[3]